newsfilter
← Latest News
GlobeNewswire·

Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708

--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera SOUTH SAN FRANCISCO, Calif. and SHAN